Updated:
Compass Therapeutics
Compass Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 in Boston, Massachusetts. The company develops antibodies targeting...
Compass Therapeutics
Compass Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 in Boston, Massachusetts. The company develops antibodies targeting biological pathways such as angiogenesis and immune system modulation. Formerly known as Kairos Biologics Foundation, Compass Therapeutics advances product candidates through clinical development as standalone and combination therapies.
General information
Firm type
Venture Capital
Year founded
2014
Location
Region
North America
Country
United States
City
Boston
Corporate office
80 Guest Street, Suite 601, Boston, MA 02135, United States
Additional offices
New York, NY, United States
Principals
Thomas J. Schuetz
Chief Executive Officer
Barry Shin
Chief Financial Officer
Arjun Prasad
Chief Commercial Officer
Cynthia Sirard
Chief Medical Officer
Bing Gong
Chief Scientific Officer
James Boylan
Director
Carl Gordon
Director
Sector focus
Frequently asked questions
Who runs investment decisions at Compass Therapeutics?
Thomas J. Schuetz, MD, PhD, co-founder and CEO, leads strategy; the board includes venture investors from OrbiMed and Borealis. No dedicated CIO is listed (per firm website).
Is Compass Therapeutics structured as a family office or a venture firm?
Compass is a clinical-stage biotechnology company, not a family office or pure venture firm. It operates with an internal R&D engine and relies on external investors for capital (per firm website).
What investment stages does Compass Therapeutics target?
Compass does not make external investments; it develops its own drug candidates from discovery through clinical trials (per firm website).
Which sectors does Compass Therapeutics explicitly avoid?
Compass focuses exclusively on therapeutic antibodies for oncology and autoimmune diseases. It does not invest in medical devices, diagnostics, or non-therapeutic biotech (per firm pipeline description).
How does Compass Therapeutics source proprietary deal flow?
Compass generates its own pipeline internally through its StitchMabs and common light chain platforms, not through external sourcing (per firm website).
Does Compass Therapeutics participate in fund commitments or only direct deals?
Compass does not function as a capital allocator. It raises equity from venture investors and public markets to fund its own internal R&D programs (per firm structure).
What is Compass Therapeutics's known posture on co-investments alongside external GPs?
Compass does not engage in co-investments. It is a single-entity drug developer, not a fund-of-funds or co-investment vehicle (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: